AzTrials
AzTrials

Acute Coronary SyndromesNCT07123181

Oregano and Basil Leaves and Coronary Artery Disease

A study testing Higher polyphenol intake by consumption of oregano and basil in people with Acute Coronary Syndromes and Unstable Angina (UA), run by Shahid Beheshti University of Medical Sciences at 1 site in Iran.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina. Read more about this study

Who is it for?
Ages 30 to 75 years
What is being tested?
Higher polyphenol intake by consumption of oregano and basil
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteIran
Study dates
1 Sep 2025to 22 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients diagnosed with unstable angina

Who cannot join

  • Patients diagnosed with STEMI
  • Patients undergoing coronary artery bypass grafting
  • Liver cirrhosis and advanced chronic kidney disease (CKD 5)
  • Having known inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis, or taking glucocorticoid medications
  • Pregnancy or breastfeeding

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Iran1 site, 1 recruiting
  • Imam Husain hospital

    Tehran, Tehran Province

    Behnaz Pourrajab, +98 9380237111, behnazpourrajab@gmail.com

    Recruiting

Other trials in Iran

About this study

Official title: Effects of Increasing Polyphenol Intake by Consumption of Oregano and Basil Leaves on Plasma Inflammatory and Lipid Factors and Total Urinary Polyphenol in Patients With Unstable Angina

The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.

Read the detailed description

Several epidemiological studies have shown an inverse relationship between polyphenol consumption and the incidence of chronic diseases, including cardiovascular disease. Dietary polyphenols can act as antioxidants, neutralizing free radicals and reactive oxygen species produced during inflammation. This can helps prevent cellular damage and alleviate oxidative stress-related inflammation. In order to increase the intake of dietary polyphenols, the consumption of vegetables and whole grains has been emphasized, along with the average amount of fruit, fungi, and algae. Moreover, it has been reported that a wider diversity of intake of polyphenols and flavonoid-rich foods when consumed together may represent the optimal approach for improving long-term health. Oregano and basil leaves are two aromatic herbs that are frequently utilized as flavorings in culinary preparations. However, in certain culinary traditions, these herbs are also consumed as part of the daily diet in the form of leafy greens. These herbs have been demonstrated to be excellent sources of polyphenols, particularly rosmarinic acid. The ingestion of these herbs has been shown to augment the dietary intake of beneficial phytochemicals and to support overall antioxidant status. . In addition, these herbs contain active compounds with potential capacity to modulate plasma lipid levels in a beneficial manner that can contribute to the protection of cardiovascular health.

Given the high content of polyphenols in basil and oregano leaves and their potential properties in reducing inflammation and modulating lipids, their consumption may help reduce risk factors associated with coronary heart disease, including unstable angina. The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.

The present study utilizes a randomized controlled clinical trial design. In this study, patients who meet the established eligibility criteria and are referred to Imam Husain hospital will be included in the study sample. Patients will be randomly assigned to one of two study groups: the control group and the herbs group. The study is scheduled to be conducted over the course of two months. The control group will receive standard medical treatment and general dietary advice, including recommendations to reduce salt, fat, and simple sugar intake. In the herbs group, in addition to the aforementioned recommendations, patients will consume 4-5 grams of dried basil leaves and 4-5 grams of oregano leaves per day. All patients will avoid taking any over-the-counter herbal medications or dietary supplements during the study.

Being tested
Control (Standard treatment), Higher polyphenol intake by consumption of oregano and basil
Medical subject headings
Acute Coronary Syndrome, Angina, Unstable

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Control (Standard treatment)Other

    Patients receive standard medical treatment.

  • Higher polyphenol intake by consumption of oregano and basilOther

    Patients consume 4-5 grams of dried oregano and 4-5 grams of dried basil leaves daily for two months in addition to their usual medical treatment.

Study groups in NCT07123181
Study groupRoleWhat they receive
ControlOtherStandard medical treatment
Receives: Other: Control (Standard treatment)
Higher polyphenol intake by consumption of oregano and basilExperimentalDaily consumption of oregano and basil leaves along with standard medical treatment
Receives: Other: Higher polyphenol intake by consumption of oregano and basil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma inflammatory biomarkers

    Plasma c-reactive protein, Interleukin-6, RANTES (CCL5)

    Measured: At the beginning of the study and two months later

  2. Plasma lipids

    Plasma concentrations of triglyceride, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol

    Measured: At the beginning of the study and two months later

Secondary outcomes (3)
  1. Plasma malondialdehyde

    Plasma concentrations of malondialdehyde

    Measured: At the beginning of the study and two months later

  2. Urinary total polyphenols

    Levels total polyphenols in spot urine sample measured by Folin-Ciocalteu method

    Measured: At the beginning of the study and two months later

  3. Plasma PCSK9 and PAI-1 levels

    plasma concentrations of proprotein convertase subtilisin/kexin type 9 (PCSK9) and plasminogen activator inhibitor 1 (PAI-1)

    Measured: At the beginning of the study and two months later

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2025
  2. Study start1 Sep 2025
  3. Primary completion28 Sep 2026 (estimated)
  4. Study completion22 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07123181
Sponsor's protocol ID
43010795
Status last verified
Aug 2025
First submitted
8 Aug 2025
Last updated
16 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Higher polyphenol intake by consumption of oregano and basil in people with Acute Coronary Syndromes and Unstable Angina (UA), run by Shahid Beheshti University of Medical Sciences at 1 site in Iran.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Behnaz Pourrajab (+989380237111, behnazpourrajab@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma inflammatory biomarkers (time frame: At the beginning of the study and two months later). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in